Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.50 |
| ▸ | PI4KA | P42356 | 7/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 7/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 7/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 7/20 | 0.50 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | AHCY | P23526 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4298072 | 0.86 | ADORA2A (0.56) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL27818519 | 0.84 | ADORA2A (0.50) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL23834271 | 0.83 | ADORA2A (0.58) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL2932822 | 0.82 | ADORA2A (0.46) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL27455290 | 0.82 | ADORA2A (0.49) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL887808 | 0.80 | ADORA2A (0.59) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL9417289 | 0.80 | ADORA2A (0.43) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29391225 | 0.80 | FGFR1 (0.68) | ADORA2AADORA1FGFR1SLC22A6 | |
| SCHEMBL2107417 | 0.80 | FGFR1 (0.68) | ADORA2AADORA1FGFR1SLC22A6 | |
| SCHEMBL9417160 | 0.79 | SLC22A6 (0.50) | ADORA2AADORA1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024114709-A1 | A CRYSTAL FORM OF A FUSED HETEROCYCLE DERIVATIVE COMPOUND | Janssen Sciences Ireland Unlimited Company (IE) | 2024-06-06 | — | — | WO | disclosed |
| EP-4347590-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2024-04-10 | — | — | EP | disclosed |
| EP-4347036-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2024-04-10 | — | — | EP | disclosed |
| EP-4255571-A1 | FUSED HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF HBV INFECTION | Janssen Sciences Ireland Unlimited Company (IE) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023169535-A1 | HEPATITIS B ANTIVIRAL AGENTS | HUAHUI HEALTH LTD. (CN) | 2023-09-14 | — | — | WO | disclosed |
| WO-2022253259-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253255-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022116998-A1 | FUSED HETEROCYCLIC DERIVATIVES AS HBV INHIBITORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022116999-A1 | FUSED HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF HBV INFECTION | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022116997-A1 | FUSED HETEROCYCLIC DERIVATIVES AND THEIR USE IN THE TREATMENT OF HBV INFECTION | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-09 | — | — | WO | disclosed |
| EP-3645516-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | Janssen Pharmaceutica NV (BE) | 2020-05-06 | — | — | EP | disclosed |
| WO-2019214610-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2019-11-14 | — | — | WO | disclosed |
| WO-2019001420-A1 | HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-03 | — | — | WO | disclosed |
| WO-2017197624-A1 | PURINE-SCAFFOLD TLR7 LIGANDS AND CONJUGATE THEREOF | SHENZHEN HORNETCORN BIOTECHNOLOGY COMPANY,CO., LTD (CN) | 2017-11-23 | — | — | WO | disclosed |
| EP-2038290-B1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES INC (US) | 2013-09-04 | — | — | EP | disclosed |
| US-8338593-B2 | Agonists; Treatment of Hepatitis C virus; phosphinate-substituted purine derivatives | GILEAD SCIENCES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090202484-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| EP-2038290-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | Gilead Sciences, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080008682-A1 | Modulators of toll-like receptor 7 | GILEAD SCIENCES, INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2008005555-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | GILEAD SCIENCES, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080008682-A1 | Modulators of toll-like receptor 7 | TLR7, TLR6, TLR3 | ADORA2A 991/4885ADORA1 1903/4885PI4KA 2642/4885 |
| US-20090202484-A1 | MODULATORS OF TOLL-LIKE RECEPTOR 7 | TLR7, TLR6, TLR3 | ADORA2A 917/4885ADORA1 1756/4885PI4KA 2452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.